Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia

  • Technology appraisal guidance
  • TA1013
  • Published: 

Tools and resources

Resource impact

Guidance into practice